首页> 外文期刊>Biomacromolecules >A Self-Targeting, Dual ROS/pH-Responsive Apoferritin Nanocage for Spatiotemporally Controlled Drug Delivery to Breast Cancer
【24h】

A Self-Targeting, Dual ROS/pH-Responsive Apoferritin Nanocage for Spatiotemporally Controlled Drug Delivery to Breast Cancer

机译:一种自定位,双ROS / pH-响应Apoferrin Nanocage用于母癌的母动控药物

获取原文
获取原文并翻译 | 示例
           

摘要

In this study, an intelligent pH and ROS dual-responsive drug delivery system based on an apoferritin (AFt) nanocage was prepared. This therapeutic system can specifically self-target 4T1 breast cancer cells by exploiting L-apoferritin receptor SCARA 5, avoiding the nonspecific binding or aggregation of nanoparticles due to the chemical functionalization for targeting. The characteristics of AFt were utilized for the simultaneous delivery of anticancer drug doxorubicin (DOX) and photosensitizer rose bengal (RB). RB exhibited efficient reactive oxygen species (ROS) generation, which can be applied to photodynamic therapy. Meanwhile, the AFt nanocage was prone to undergoing peptide backbone cleavage when oxidized by ROS. Therefore, by combining the intrinsic pH-responsive property of AFt, the dual ROS/pH-responsive system was developed. The time and location of drug release can be controlled by the combination of internal and external stimulus, which avoids the incomplete drug release under single stimulus response. The drug release rate increased significantly (from 26.1% to 92.0%) under low-pH condition (pH 5.0) and laser irradiation. More DOX from AFt entered the nucleus and killed the tumor cells, and the cell inhibition rate was up to similar to 83% (DOX concentration: 5 mu g/mL) after 48 h incubation. In addition, the biodistribution and the in vivo antitumor efficacy (within 14 d treatment) of the nanosystem were investigated in 4T1 breast cancer BALB/c mice. The results indicated that the system is a promising therapeutic agent involving ROS/pH dual response, self-targeting, and chemo-photodynamic therapy.
机译:在该研究中,制备基于Apoferritin(AFT)纳米证的智能pH和ROS双响应药物递送系统。这种治疗系统可以通过利用L-Apoferrin受体瘢痕5来特异性自靶4T1乳腺癌细胞,避免由于靶向的化学官能化引起的纳米颗粒的非特异性结合或聚集。 AFT的特征用于同时递送抗癌药物Doxorubicin(DOX)和光敏剂升降(RB)。 RB表现出高效的反应性氧(ROS)产生,可应用于光动力治疗。同时,当通过ROS氧化时,AFT纳米可以易于探讨肽骨干裂解。因此,通过组合AFT的内在pH响应性,开发了双ROS / pH响应系统。药物释放的时间和地点可以通过内部和外部刺激的组合来控制,这避免了单刺激反应下的不完全药物释放。在低pH条件下(pH5.0)和激光照射,药物释放速率显着增加(从26.1%至92.0%)。从Aft孵育后,从Aft进入细胞核并杀死肿瘤细胞,并且细胞抑制率达到83%(DOX浓度:5μg/ ml)。此外,在4T1乳腺癌BALB / C小鼠中研究了纳米系统的生物分布和体内抗肿瘤功效(14d处理中)。结果表明该系统是涉及ROS / pH双响应,自定位和化学光动力疗法的有前途的治疗剂。

著录项

  • 来源
    《Biomacromolecules》 |2018年第3期|共11页
  • 作者单位

    Zhengzhou Univ Sch Pharmaceut Sci 100 Sci Rd Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Sch Pharmaceut Sci 100 Sci Rd Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Sch Pharmaceut Sci 100 Sci Rd Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Sch Pharmaceut Sci 100 Sci Rd Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Sch Pharmaceut Sci 100 Sci Rd Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Sch Pharmaceut Sci 100 Sci Rd Zhengzhou 450001 Henan Peoples R China;

    Zhengzhou Univ Sch Pharmaceut Sci 100 Sci Rd Zhengzhou 450001 Henan Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号